Monday, 4 September 2017

#ResearchSpeak & #ECTRIMS2017: late-breakers at ECTRIMS 2017

What do you think of the late-breaking news scientific programme at ECTRIMS next month? 



CoI: multiple

12 comments:

  1. Nothing on HSCT or B-cells? What is happening to the priorities of the MS community?

    ReplyDelete
    Replies
    1. This refers the late-breaking presentations.

      When I searched the programme the following topic had HSCT in the title.

      Autologous haematopoietic stem cell transplantation (AHSCT) in relapse remitting (RR-MS) and secondary progressive multiple sclerosis (SP-MS): a phase II trial from St Vincent's Hospital, Sydney Australia J. Massey (Sydney, AU).

      In comparison there were 12 references to B cells in the programme.

      http://www.professionalabstracts.com/ectrims2017/programme-ectrims2017.pdf

      Delete
    2. You should check out the EBMT meetings for hsct
      This is mainly an neuro meeting they dont bother with hsct

      Delete
  2. Did Barts submit any late-breaking data? Something on B-cells or cladribine?

    ReplyDelete
    Replies
    1. I was thinking exactly the same thing.

      Delete
    2. Yes, we did. One of the research fellows will be presenting a poster on the data.

      Cladribine controls multiple sclerosis via memory B cell depletion B. Ceronie (London, UK)

      Delete
    3. Too controversial to be presented to the "Great and the Good" as a platform :-(

      Delete
  3. I'm very interested to learn the topline results of the Ibudilast trial. Have you seen anything that hints to success/failure?

    ReplyDelete
    Replies
    1. No I haven't seen any thing about the tiral but I will soon do a post on the target

      Delete
  4. Hardly late breaking for the Ozanimod trial (positive). It was announced by Cellgene as being positive on 25 March which was before the abstract deadline for the main meeting

    GNBca1 results were announced August (failure), so a boring 15 minutes

    MRI in primates is really going to get the juices going of your average neurologist

    MOG antibody induced disease is often an NMO-like condition#

    Does neurofilament levels reflect efficacy in RR disease...yes

    Fingolimod in peadiatric MS we can guess too

    ReplyDelete
    Replies
    1. I can tell MD is not so enthusiastic to attend the session. May be an early return or a late sleep would be better for you.

      Delete
    2. We all want to know about Ibudilast in Progressive MS but am a bit disappointed by the men in grey's choices our story is cracking

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.